



1-800-533-1710

Early Onset IBD Gene Panel

EOIBD

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N022000304
PATIENT ID X100420057	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TEST
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:34 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER X100420057 CLIENT MRN 321

TEST DESCRIPTION

Evaluation of 107 genes associated with monogenic early onset inflammatory bowel disease

SPECIMEN

WB Whole Blood

RESULT SUMMARY

Pathogenic Variant Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
G6PC3 (NM_138387.3)	c.778G>C p.Gly260Arg (p.G260R) Chr17(GRCh37):g.42153148G>C	Heterozygous	Pathogenic

The following heterozygous PATHOGENIC variant was detected:

G6PC3 (NM_138387.3), chr17(GRCh37):g.42153148G>C, c.778G>C, p.Gly260Arg (p.G260R)

No additional reportable variants were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by this assay.

INTERPRETATION

G6PC3 c.778G>C (p.Gly260Arg), PATHOGENIC

The heterozygous c.778G>C (p.Gly260Arg) missense variant in the G6PC3 gene (MIM:611045) is classified as pathogenic. The G6PC3 gene encodes the catalytic subunit of glucose-6-phosphatase (G6Pase). G6Pase is located in the endoplasmic reticulum (ER) and catalyzes the hydrolysis of glucose-6-phosphate to glucose and phosphate in the last step of the gluconeogenic and glycogenolytic pathways. Pathogenic variants in this gene result in autosomal recessive severe congenital neutropenia 4 (SCN4), which may also present with extra-hematological clinical features such as cardiac findings and inflammatory bowel disease. This variant has been reported in the homozygous and compound heterozygous state in numerous patients with severe congenital neutropenia, and functional studies demonstrate that this variant abolishes enzyme activity (1-8). This variant has been observed at a very low frequency in exome and/or genome sequencing data gathered from large, multi-ethnic cohorts, suggesting it is a rare variant (9,10). This result is supportive of carrier status for autosomal recessive severe congenital neutropenia 4. However, the presence of an undetectable second variant cannot be ruled out. Clinical correlation is recommended.

Individuals may have a pathogenic variant in one of the interrogated genes that is not detectable by the methods utilized. Additionally, the clinical phenotype that is observed in this individual and/or family may be due to a pathogenic variant or



1-800-533-1710

Early Onset IBD Gene Panel

EOIBD

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N022000304
PATIENT ID X100420057	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TEST
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:34 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420057
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321

variants in another gene not targeted by this test.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.

REFERENCES:

- 1) Boztug K, Appaswamy G, Ashikov A, et al. A syndrome with congenital neutropenia and mutations in G6PC3 [published correction appears in N Engl J Med. 2011 Apr 28;364(17):1682]. N Engl J Med. 2009;360(1):32-43. doi:10.1056/NEJMoa0805051 (PMID 19118303)
- 2) Xia J, Bolyard AA, Rodger E, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol. 2009;147(4):535-542. doi:10.1111/j.1365-2141.2009.07888.x (PMID 19775295)
- 3) McDermott DH, De Ravin SS, Jun HS, et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood. 2010;116(15):2793-2802. doi:10.1182/blood-2010-01-265942 (PMID 20616219)
- 4) Bégin P, Patey N, Mueller P, et al. Inflammatory bowel disease and T cell lymphopenia in G6PC3 deficiency. J Clin Immunol. 2013;33(3):520-525. doi:10.1007/s10875-012-9833-6 (PMID 23180359)
- 5) Estévez OA, Ortega C, Tejero Á, et al. A novel phenotype variant of severe congenital neutropenia caused by G6PC3 deficiency. Pediatr Blood Cancer. 2013;60(7):E29-E31. doi:10.1002/pbc.24499 (PMID 23441086)
- 6) Banka S, Newman WG. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations. Orphanet J Rare Dis. 2013;8:84. Published 2013 Jun 13. doi:10.1186/1750-1172-8-84 (PMID 23758768)
- 7) Desplantes C, Fremond ML, Beaupain B, et al. Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French Severe Congenital Neutropenia Registry. Orphanet J Rare Dis. 2014;9:183. Published 2014 Dec 10. doi:10.1186/s13023-014-0183-8 (PMID 25491320)
- 8) Lin SR, Pan CJ, Mansfield BC, Chou JY. Functional analysis of mutations in a severe congenital neutropenia syndrome caused by glucose-6-phosphatase- β deficiency. Mol Genet Metab. 2015;114(1):41-45. doi:10.1016/j.ymgme.2014.11.012 (PMID 25492228)
- 9) dbSNP: www.ncbi.nlm.nih.gov/snp; Sherry ST, Ward M and Sirotkin K. dbSNP-Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation. Genome Res. 1999;9:677-679 (PMID 10447503)
- 10) gnomAD Browser: gnomad.broadinstitute.org/; Karczewski K, Francioli LC, MacArthur DG, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443 (PMID 32461654)



1-800-533-1710

Early Onset IBD Gene Panel

EOIBD

PATIENT NAME TESTRNV, IMPLEMENTATION					ORDER NUMBER N022000304
PATIENT ID X100420057	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TEST	
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:34 AM			
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER X100420057	
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN 321	

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. NGS and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID EOIBD) for details regarding genes with regions not routinely covered.

GENES ANALYZED

ADA, ADAM17, AICDA, AIRE, ALPI, ANKZF1, ARPC1B, ASAH1, BACH2, BTK, CARMIL2, CASP8, CD3G, CD40LG, CD55, COL7A1, CTLA4, CYBA, CYBB, CYBC1, DCLRE1C, DEF6, DGAT1, DKC1, DOCK8, DUOX2, EPCAM, FCHO1, FERMT1, FOXP3, G6PC(G6PC1), G6PC3, GUCY2C, HPS1, HPS3, HPS4, HPS6, ICOS, IFIH1, IKBKG, IL10, IL10RA, IL10RB, IL21, IL21R, IL2RA, IL2RB, IL2RG, IL7R, ITCH, ITGB2, JAK1, LCT, LIG4, LRBA, MALT1, MEFV, MVK, MYO5B, NCF2, NCF4, NEUROG3, NFKBIA, NLRC4, PAX1, PCSK1, PIK3CD, PIK3R1, PLCG2, PLVAP, POLA1, RAG1, RAG2, RIPK1, RTEL1, SH2D1A, SI, SKIV2L, SLC10A2, SLC26A3, SLC37A4, SLC39A4, SLC51B, SLC5A1, SLC9A3, SPINT2, STAT1, STAT3, STAT5B, STIM1, STX3, STXBP2, TGFB1, TGFB1R1, TGFB1R2, TLR3, TNFAIP3, TRIM22, TRNT1, TTC37, TTC7A, UNC45A, WAS, WIPF1, XIAP, ZAP70 and ZBTB24

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive



1-800-533-1710

Early Onset IBD Gene Panel

EOIBD

PATIENT NAME TESTRNV, IMPLEMENTATION				ORDER NUMBER N022000304
PATIENT ID X100420057	DATE OF BIRTH 02/19/1968	AGE 55 Y	SEX Male	REQUESTED BY CLIENT TEST
COLLECTED 5/22/2023, 6:33 AM	RECEIVED 5/22/2023, 12:21 PM	REPORTED 5/24/2023, 10:34 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER X100420057 CLIENT MRN 321

results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Early Onset IBD Panel in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID EOIBD) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

Ann Marie Moyer, M.D., Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM G MORICE MD, PHD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905